Category: catalyst-ligand

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63-91-2,L-Phenylalanine,as a common compound, the synthetic route is as follows.

63-91-2, The commercially available raw materials L-phenylalanine (LOBA,99%) and D-methionine (LOBA, 99%) in the purest form were taken in an equimolar (1:1) ratio and dissolved in the double distilled water. After continuous stirring for 8 h at room temperature homogenous saturated solution was obtained which was then filtered in the vessel using whatman filter paper at room temperature. After a time span of30 days optically good quality crystals were harvested from the mother solution by solution evaporation method.

As the paragraph descriping shows that 63-91-2 is playing an increasingly important role.

Reference：
Article; Sangeetha; Jayaprakash; Nageshwari; Rathika Thaya Kumari; Sudha; Prakash; Vinitha; Lydia Caroline; Physica B: Condensed Matter; vol. 525; (2017); p. 164 – 174;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

22348-32-9, (R)-Diphenyl(pyrrolidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3A. Preparation of TMS-prolinolTo a mixture of prolinol (10.0 g, 39.5 mmol) and imidazole (4.57 g, 67.1 mmol) in THF (100 mL) was added chlorotrimethylsilane (5.57 g, 51.3 mmol) over 15 min while maintaining the batch temperature below 30 0C. The resulting slurry was aged at 50 0C for 3-5 h. The reaction mixture was cooled to ambient tempearture and quenched by addition of MTBE (50 mL) and 15% aq NaCl (100 mL). The organic layer was washed with 15% aq NaCl (50 mL). The solution was azeotropically dried at the constant volume by feeding THF.HPLC MethodColumn: Ascentis Express Cl 8 (100×4.6mm, 2.7um)Column temperature: 45 0CFlow rate: 1.5 ml/minDetection: UV at 210nmGradient:Time(min) 0.1% H^PO4 (0A) MeCN (0A)0 95 51 95 512 10 90Retention times (minutes): prolinol (4.8 min); TMS prolinol (7.3 min), 22348-32-9

The synthetic route of 22348-32-9 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; MERCK SHARP &; DOHME CORP.; XU, Feng; DESMOND, Richard; HOERRNER, R. Scott; HUMPHREY, Guy, R.; ITOH, Tetsuji; JOURNET, Michel; YOSHIKAWA, Naoki; ZACUTO, Michael, J.; WO2010/144293; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, General procedure: A solution of cis-RuII(bpz)2Cl2 (100 mg, 0.205 mmol) and AgNO3 (77 mg, 0.453 mol) in water (25 mL) was heated at reflux for 48 h. After cooling to room temperature, the mixture was filtered through Celite to remove AgCl, and the filtrate was evaporated to dryness. The residue was dissolved in DMF (15 mL) and the solution purged with argon for 15 min. 4,4?-bis(trifluoromethyl)-2,2?-bipyridyl (121 mg, 0.414 mmol) was added and the mixture heated at 100 °C for 24 h under argon. After cooling to room temperature, the solution was evaporated under vacuum to a small volume and diethyl ether (150 mL) added. The precipitate was filtered off and dissolved in a minimum of cold water to which solid NH4PF6 was added. The solid was filtered off and purified by column chromatography as for 1 to give an orange solid. Yield: 73 mg (35percent).

The synthetic route of 71071-46-0 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Coe, Benjamin J.; Peers, Martyn K.; Scrutton, Nigel S.; Polyhedron; vol. 96; (2015); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937.

22348-32-9, As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

71071-46-0, Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

71071-46-0, General procedure: A solution of compound 5 (400mg, 0.822mmol), [(eta6-p-cymene) RuCl2]2 (252mg, 0.411mmol), and Me4NCl (450mg, 4.11mmol) in anhydrous acetone (21mL) was stirred under a dark atmosphere at room temperature for 6h. The reaction mixture was filtered and the filtrate was evaporated to afford crude compound as a bright orange solid. The above intermediate (200mg, 0.373mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (203mg, 0.746mmol), and potassium hexafluorophosphate (103mg, 0.56mmol) were dissolved in dry 1,2-dichloroethane (20mL) and the mixture was stirred at 60°C for 12h. The mixture was then concentrated under reduced pressure and the resulting crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 6 as a dark red solid (233mg, 70percent). 1H NMR (300MHz, CDCl3): delta 8.89 (s, 1H), 8.85 (s, 1H), 8.79 (s, 1H), 8.74 (s, 1H), 8.39 (d, J=5.7Hz, 1H), 8.00?7.91 (m, 3H), 7.82 (m, 3H), 7.67 (dd, J=3.6Hz, 1.5Hz, 1H), 7.52 (dt, J=8.7Hz, 1.2Hz, 1H), 7.46 (d, J=7.5Hz, 1H), 7.32?7.19 (m, 5H), 7.13 (d, J=5.7Hz, 1H), 6.72 (dt, J=6.5Hz, 1.5Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 1.27 (s, 3H); 13C NMR (125MHz, CDCl3): delta 192.8, 164.6, 164.4, 164.2, 162.6, 157.9, 157.8, 156.5, 156.3, 155.6, 151.9, 151.4, 150.5, 149.8, 142.5, 142.4, 138.4, 137.3, 136.6, 135.6, 135.3, 135.0, 134.9, 129.4, 128.5, 127.9, 127.6, 126.3, 162.2, 125.8, 123.0, 122.9, 122.4, 120.4, 118.8, 53.6, 53.5, 53.4, 53.3, 15.5; HRMS (FAB):calcd. for C44H36N5O8RuS [M+] 896.1328, found 896.1321.

As the paragraph descriping shows that 71071-46-0 is playing an increasingly important role.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63-91-2,L-Phenylalanine,as a common compound, the synthetic route is as follows.

63-91-2, The commercially available raw materials L-phenylalanine (LOBA,99%) and D-methionine (LOBA, 99%) in the purest form were taken in an equimolar (1:1) ratio and dissolved in the double distilled water. After continuous stirring for 8 h at room temperature homogenous saturated solution was obtained which was then filtered in the vessel using whatman filter paper at room temperature. After a time span of30 days optically good quality crystals were harvested from the mother solution by solution evaporation method.

As the paragraph descriping shows that 63-91-2 is playing an increasingly important role.

Reference：
Article; Sangeetha; Jayaprakash; Nageshwari; Rathika Thaya Kumari; Sudha; Prakash; Vinitha; Lydia Caroline; Physica B: Condensed Matter; vol. 525; (2017); p. 164 – 174;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI